Evaluation of a maleimido derivative of CHX-A″ DTPA for site-specific labeling of affibody molecules

Bioconjugate Chemistry

Volumn 19, Issue 8, 2008, Pages 1579-1587

  Tolmachev, Vladimir ^a,b,c   Xu, Heng ^d   Wållberg, Helena ^b   Ahlgren, Sara ^c   Hjertman, Magnus ^b   Sjöberg, Anna ^b   Sandström, Mattias ^e   Abrahmsén, Lars ^b   Brechbiel, Martin W ^d   Orlova, Anna ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CELL CULTURE; DISSOCIATION; MAMMALS; MOLECULES; TUMORS;

AFFIBODY MOLECULES; BUNDLE STRUCTURES; HELIX BUNDLE; IN-VIVO; LABELINGS; MOLECULE BINDING; PHAGE DISPLAY TECHNOLOGY; POST INJECTION; SITE-SPECIFIC; TUMOR ANTIGEN;

AMINO ACIDS;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Z 2395 C INDIUM 111; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; PENTETIC ACID Z 2395 C INDIUM 111; PENTETIC ACID Z 432 INDIUM 111; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; DISSOCIATION CONSTANT; DRUG BINDING; DRUG CLEARANCE; DRUG CONJUGATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; KIDNEY; MOUSE; NONHUMAN; OVARY CANCER; RADIOACTIVITY; ROOM TEMPERATURE; SCINTISCANNING; TUMOR XENOGRAFT;

MUS;

EID: 50249141746     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800110y     Document Type: Article

References (48)

1. Tolmachev, V., Orlova, A., Nilsson, F. Y., Feldwisch, J., Wennborg, A., and Abrahmsén, L. (2007) Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin. Biol. Ther. 7, 555-568.
2. Nilsson, F. Y., and Tolmachev, V. (2007) Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr. Opin. Drug Discovery Dev. 10, 167-175.
3. Orlova, A., Feldwisch, J., Abrahmsén, L., and Tolmachev, V. (2007) Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother. Radiopharm. 22, 573-584.
4. Orlova, A., Magnusson, M., Eriksson, T. L., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., and Nilsson, F. Y. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66, 4339-4348.
5. Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandström, M., Nilsson, F. Y., Wennborg, A., Abrahmsén, L., and Feldwisch, J. (2007) Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 67, 2178-2186.
6. Friedman, M., Nordberg, E., Höidén-Guthenberg, I., Brismar, H., Adams, G. P., Nilsson, F. Y., Carlsson, J., and Ståhl, S. (2007) Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng. Des. Sel. 20, 189-199.
7. Nordberg, E., Friedman, M., Göstring, L., Adams, G. P., Brismar, H., Nilsson, F. Y., Ståhl, S., Glimelius, B., and Carlsson, J. (2007) Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl. Med. Biol. 34, 609-618.
8. Friedman, M., Orlova, A., Johansson, E., Eriksson, T., Höidén-Guthenberg, I., Tolmachev, V., Nilsson, F. Y., and Ståhl S. (2008) Directed evolution to low nanomolar affinity of an epidermal growth factor receptor 1-binding Affibody molecule. J. Mol. Biol. 376, 1388-1402.
9. Mume, E., Orlova, A., Larsson, B., Nilsson, A. S., Nilsson, F. Y., Sjöberg, S., and Tolmachev, V. (2005) Evaluation of ((4-hydroxyphenyl) ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjugate Chem. 16, 1547-1555.
10. Orlova, A., Nilsson, F. Y., Wikman, M., Widström, C., Ståhl, S., Carlsson, J., and Tolmachev, V. (2006) Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J. Nucl. Med. 47, 512-519.
11. 99mTc- chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur. J. Nucl. Med. Mol. Imaging 34, 722-733.
12. Tran, T., Orlova, A., Sivaev, I., Sandström, M., and Tolmachev, V. (2007) Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. Int. J. Mol. Med. 19, 485-493.
13. Tran, T., Engfeldt, T., Orlova, A., Widström, C., Bruskin, A., Tolmachev, V., and Karlström, A. E. (2007) In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjugate Chem. 18, 549-558.
14. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur. J. Nucl. Med. Mol. Imaging 34, 1843-1853.
15. HER2:342, a potential agent for imaging of HER2 expression in malignant tumors. Int. J. Mol. Med. 20, 397-404.
16. HER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjugate Chem. 18, 1956-1964.
17. 111In-benzyl-DTPA- ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J. Nucl. Med. 47, 846-853.
18. 114mIn]CHX- A″-DTPA-ZHER2:342, an Affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Q. J. Nucl. Med. Mol. Imaging 51, 314-323.
19. Lundberg, E., Höidén-Guthenberg, I., Larsson, B., Uhlén, M., and Gräslund, T. (2007) Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol. Methods. 319, 53-63.
20. Ahlgren, S., Orlova, A., Rosik, D., Sandström, M., Sjöberg, A., Baastrup, B., Widmark, O., Fant, G., Feldwisch, J., and Tolmachev, V. (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjugate Chem. 19, 235-243.
21. Adams, G. P., Shaller, C. C., Dadachova, E., Simmons, H. H., Horak, E. M., Tesfaye, A., Klein-Szanto, A. J., Marks, J. D., Brechbiel, M. W., and Weiner, L. M. (2004) A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 64, 6200-6206.
22. Parry, R., Schneider, D., Hudson, D., Parkes, D., Xuan, J. A., Newton, A., Toy, P., Lin, R., Harkins, R., Alicke, B., Biroc, S., Kretschmer, P. J., Halks-Miller, M., Klocker, H., Zhu, Y., Larsen, B., Cobb, R. R., Bringmann, P., Roth, G., Lewis, J. S., Dinter, H., and Parry, G. (2005) Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res. 65, 8397-8405.
23. Xu, H., Baidoo, K. E., Wong, K. J., and Brechbiel, M. W. (2008) A novel bifunctional maleimido CHX-A″ chelator for conjugation to thiol-containing biomolecules. Bioorg. Med. Chem. Lett. 18, 2679-83.
24. 177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur. J. Nucl. Med. Mol. Imaging 32, 1457-1462.
25. HER2:342-pep2: implications for development of labeled tracers, Cancer Biother. Radiopharm., in press.
26. Shin, L. B., Thorpe, S. R., Griffiths, G.L., Diril, H., Ong, G. L., Hansen, H. J., Goldenberg, D. M., and Mattes, M. J. 1994) The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J. Nucl. Med. 35, 899-908.
27. Aunoble, B., Sanches, R., Didier, E., and Bignon, Y. J. (2000) Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int. J. Oncol. 16, 567-576.
28. Carlsson, J., Nordgren, H., Sjostrom, J., et al. (2004) HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br. J. Cancer 90, 2344.
29. Gardmark, T., Wester, K., de la Torre, M., Carlsson, J., and Malmstrom, P. U. (2005) Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int. 95, 982-986.
30. Brechbiel, M. W., and Waldmann, T. A. (2000) Anti-HER2 radioimmunotherapy. Breast Dis. 11, 125-132.
31. Milenic, D. E., Garmestani, K., Brady, E. D., Albert, P. S., Ma, D., Abdulla, A., and Brechbiel, M. W. (2004) Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 10, 7834-7841.
32. 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 67, 2773-2782.
33. 212Pu-labeled radioimmunoconjugate targeting HER2. Cancer Biother. Radiopharm. 20, 557-568.
34. Mandler, R., Wu, C., Sausville, E. A., Roettinger, A. J., Newman, D. J., Ho, D. K., King, C. R., Yang, D., Lippman, M. E., Landolfi, N. F., Dadachova, E., Brechbiel, M. W., and Waldmann, T. A. (2000) Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J. Natl. Cancer. Inst. 92, 1573-1581.
35. Bast, R. C. Jr., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H.Jr., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., and Somerfield, M. R. (2001) American society of clinical oncology tumor markers expert panel 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the american society of clinical oncology. J.Clin. Oncol 19, 1865-1878.
36. Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., and Gion, M. (2005) Tumor markers in breast cancer-European group on tumor markers recommendations. Tumour Biol. 26, 281-293.
37. Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., and Jenkins, R. B. (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J. Clin. Oncol. 24, 3032-3038.
38. Behr, T. M., Behe, M., and Wormann, B. (2001) Trastuzumab and breast cancer. N. Engl. J. Med. 345, 995-996.
39. Nikula, T. K., McDevitt, M. R., Finn, R. D., Wu, C., Kozak, R. W., Garmestani, K., Brechbiel, M. W., Curcio, M. J., Pippin, C. G., Tiffany-Jones, L., Geerlings, M. W. Sr., Apostolidis, C., Molinet, R., Geerlings, M. W. Jr., Gansow, O. A., and Scheinberg, D. A. (1999) Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med. 40, 166-176.
40. 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. 29, 431-442.
41. 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor - expressing breast carcinomas. Clin. Cancer Res. 13, 6070-6079.
42. Valkema, R., De Jong, M., Bakker, W. H., Breeman, W. A., Kooij, P. P., Lugtenburg, P. J., De Jong, F. H., Christiansen, A., Kam, B. L., De Herder, W. W., Stridsberg, M., Lindemans, J., Ensing, G., and Krenning, E. P. (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience. Semin. Nucl. Med. 32, 110-122.
43. Kwekkeboom, D. J., Mueller-Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S., Kvols, L. K., O'dorisio, T. M., Valkema, R., Bodei, L., Chinol, M., Maecke, H. R., and Krenning, E. P. (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med. 46 (Suppl 1), 62S-66S.
44. Clifford, T., Boswell, C. A., Biddlecombe, G. B., Lewis, J. S., and Brechbiel, M. W. (2006) Validation of a novel CHX-A″ derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX- A″-octreotide. J. Med. Chem. 49, 4297-4304.
45. 90Y-CHX-A″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin. Cancer Res. 11, 7080s-7086s.
46. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60, 6095-6100.
47. 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin. Cancer Res. 13, 5604s-5612s.
48. Feldwisch, J., Unpublished results.